SCHEMBL3459745

SCHEMBL3459745

CNC(=O)c1nc(-c2cccc(C(=O)NCc3cccc(OCCN4CCOCC4)c3)c2)cnc1N

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 2/20 0.59
ROCK2 O75116 1/20 0.59
ATR Q13535 7/20 0.50
HDAC1 Q13547 2/20 0.49
KDM1A O60341 1/20 0.49
MAP4K4 O95819 1/20 0.48
AURKA O14965 1/20 0.47
RPS6KB1 P23443 1/20 0.47
GRK5 P34947 1/20 0.46
KDR P35968 1/20 0.46
SRC P12931 1/20 0.45
PIK3CD O00329 2/20 0.45
PIK3CA P42336 2/20 0.45
PIK3CG P48736 2/20 0.45
PIK3CB P42338 1/20 0.44
ACVR1 Q04771 1/20 0.44
MAPK14 Q16539 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3461492 0.93 HDAC1 (0.57) ROCK1ROCK2ATRHDAC1KDM1A
SCHEMBL3822499 0.90 PIK3CD (0.52) ROCK1ROCK2ATRHDAC1PIK3CD
SCHEMBL3469202 0.87 ATR (0.49) ROCK1ROCK2ATRPIK3CDPIK3CA
SCHEMBL3460166 0.87 ATR (0.52) ATRMAP4K4GRK5PIK3CDPIK3CA
SCHEMBL3460819 0.84 ATR (0.64) ATRHDAC1KDM1APIK3CDPIK3CA
SCHEMBL3461445 0.83 AURKA (0.59) ROCK1ROCK2ATRAURKAGRK5
SCHEMBL3460624 0.83 ATR (0.59) ATRHDAC1KDM1APIK3CDPIK3CA
SCHEMBL3461852 0.82 CCNE2 (0.59) ATRMAP4K4PIK3CDPIK3CAPIK3CG
SCHEMBL3459600 0.82 ATR (0.45) ROCK1ROCK2ATRHDAC1MAP4K4
SCHEMBL3461064 0.82 PIK3CD (0.52) ROCK2ATRAURKAPIK3CDPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501514-B1 PROTEIN KINASE MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2012-12-19 EP claimed
US-20060211709-A1 Protein kinase modulators and methods of use EXELIXIS, INC. 2006-09-21 US claimed
EP-1501514-B1 PROTEIN KINASE MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2012-12-19 EP disclosed
US-7704995-B2 Protein kinase modulators and methods of use EXELIXIS, INC. (US) 2010-04-27 US disclosed
EP-1501514-A4 PROTEIN KINASE MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2009-08-26 EP disclosed
US-20060211709-A1 Protein kinase modulators and methods of use EXELIXIS, INC. 2006-09-21 US disclosed
EP-1501514-A2 PROTEIN KINASE MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2005-02-02 EP disclosed
WO-2003093297-A2 PROTEIN KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2003-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211709-A1 Protein kinase modulators and methods of use GRK2, MAP4K2, MAPKAPK2 ROCK1 1172/4885ROCK2 739/4885ATR 556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.